<DOC>
	<DOCNO>NCT01018979</DOCNO>
	<brief_summary>A phase II study evaluate safety , pharmacokinetics , hematopoietic stem cell mobilization TG-0054 patient multiple myeloma , non-Hodgkin lymphoma Hodgkin disease .</brief_summary>
	<brief_title>Safety PK/PD TG-0054 Multiple Myeloma , Non-Hodgkin Lymphoma Hodgkin Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Male female 18 70 year age inclusive Patients confirm pathology diagnosis MM , NHL HD Potential candidate autologous stem cell transplantation Investigator 's discretion ≦ 2 prior regimen cytotoxic chemotherapy ( rituximab , thalidomide , bortezomib consider cytotoxic chemotherapy ) &gt; 4 week since last cycle chemotherapy prior study drug administration Total dose melphalan receive ≦ 200 mg recent chemotherapy treatment Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Recovered acute toxic effect prior chemotherapy Investigator 's discretion White blood cell ( WBC ) count ≧ 3.0 x 109/L screen laboratory assessment Absolute neutrophil count ≧ 1.5 x 109/L screen laboratory assessment Platelet count ≧ 100 x 109/L screen laboratory assessment Serum creatinine ≦ 2.2 mg/dL screen laboratory assessment Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , total bilirubin &lt; 2 x upper limit normal ( ULN ) screen laboratory assessment Negative human immunodeficiency virus ( HIV ) Adequate cardiac pulmonary function undergo leukapheresis Investigator 's discretion For female , one follow criterion must fulfil : 1 . At least one year postmenopausal , 2 . Surgically sterile , 3 . Willing use doublebarrier method [ intrauterine device ( IUD ) plus condom , spermicidal gel plus condom ] contraception throughout study Males must willing use reliable form contraception ( use condom partner fulfil criterion ) study Day 1 28 day last dose TG0054 Able provide sign informed consent Received radiation therapy around pelvic spinal area within 6 month prior study drug administration &gt; 10 % bone marrow involvement lymphoma NHL patient Failed previous stem cell collection [ fail collect 2 x 106 CD34+ cells/kg within 4 apheresis session receive granulocyte colonystimulating factor ( GCSF ) ] Patients undergone previous stem cell transplantation procedure Received GCSF within 2 week prior study drug administration History cancer within past 5 year exclude MM , NHL , HD , basal cell squamous cell carcinoma skin History hematologic disorder include bleed thromboembolic disease History poor uncontrollable cardiovascular pulmonary disease myocardial infarction , cardiac arrhythmia , transient ischemic attack , stroke Chronic Obstructive Pulmonary Disease ( COPD ) patient hospitalize two time year due underlying disease Diagnosis sickle cell anemia document sickle cell trait Uncontrollable malignancy MM , NHL HD , carcinomatous meningitis , Investigator 's discretion Any infection require antibiotic treatment unexplained fever 38 °C within 3 day prior dose Pregnant breastfeed Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious disease ) illness must enrol study Received investigational drug within 1 month enter study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>